RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:What a negative board now.....Quattro74 wrote: Jaro1977 wrote: Agree Quattro.
That TLD-1433 is being used in a study for nsclc at a leading cancer centre in the US is what reinforces why we are here for the potential greatness of Dr. Sherri's work.
Whenever I get down and frustrated by the stupidly low sp, recent bumble, fumble of the trial, I go re-read all the studies, peer reviews, other case use papers.
Remember, 2 people are (hopefully) still CR at over 2 years.
People come in all shapes, sizes and baldders differ. Were you ever the guy at the bar that had to piss 3-4 times more than your buddies? The team made a mistake in how to calculate the amount of TLD, light and exposure for the various sized bladders and still, still seemed to have 4 at 100% CR at 90days!
This has been caught and should be rectified going forward. Trials are performed to refine the process to prove the method, science. That is what is happening
When I first heard of Roswell Park and that they would be studying 1433 in a phase 1, and I had learned of that British Vaccine for nmibc that would do away with BCG and potentially half of TLT's nmibc market, I knew the way forward would probably be nsclc. I still thought they'e do better and get the SP moving with this phase 2. Didn't expect the fumble. NSCLC market is 20-30x bigger than 100% of NMIBC/MIBC.
Hey Quattro...Which vaccine are you referring to....the VPM1002bc (a recombinant/modified BCG vaccine)? I think an impact of "half of TLT's NMIBC market" is on the high end. In general, BCG vaccines & its modified versions do require "a lot" of instillations (for immune boosting). The updated VPM1002bc vaccine, which is currently still under clinical investigation, would require 15 instillations in the first 12 months. My guess is many patients won't comply to that kind of regimen. Some will also have adverse effects that will either eliminate that option altogether or simply reduce compliance further. There is also the concern of recombinant BCG manufacturing capacity/reliability. Lastly, if TLT can achieve superior efficacy in the context of a worldwide BCG shortage, there will likely be opportunities for "first-line" therapeutic use of our ACT.
If Roswell progresses as planned, I agree...BCG-unresponsive NMIBC becomes just an appetizer.